Fintel reports that on November 10, 2025, Needham maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation.
Analyst Price Forecast Suggests 49.38% Upside
As of November 8, 2025, the average one-year price target for CRISPR Therapeutics is $82.34/share. The forecasts range from a low of $32.32 to a high of $281.40. The average price target represents an increase of 49.38% from its latest reported closing price of $55.12 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for CRISPR Therapeutics is 13,142MM, an increase of 34,438.76%. The projected annual non-GAAP EPS is -6.65.
What is the Fund Sentiment?
There are 658 funds or institutions reporting positions in CRISPR Therapeutics. This is an increase of 104 owner(s) or 18.77% in the last quarter. Average portfolio weight of all funds dedicated to CRSP is 0.25%, an increase of 22.09%. Total shares owned by institutions increased in the last three months by 13.93% to 93,309K shares. 
The put/call ratio of CRSP is 0.47, indicating a bullish outlook.
What are Other Shareholders Doing?
ARK Investment Management holds 10,183K shares representing 11.20% ownership of the company. In its prior filing, the firm reported owning 10,165K shares , representing an increase of 0.17%. The firm increased its portfolio allocation in CRSP by 4.87% over the last quarter.
ARKK - ARK Innovation ETF holds 7,626K shares representing 8.38% ownership of the company. In its prior filing, the firm reported owning 6,341K shares , representing an increase of 16.85%. The firm increased its portfolio allocation in CRSP by 10.78% over the last quarter.
Capital International Investors holds 5,594K shares representing 6.15% ownership of the company. In its prior filing, the firm reported owning 6,073K shares , representing a decrease of 8.57%. The firm increased its portfolio allocation in CRSP by 15.31% over the last quarter.
T. Rowe Price Investment Management holds 3,683K shares representing 4.05% ownership of the company. In its prior filing, the firm reported owning 3,798K shares , representing a decrease of 3.12%. The firm increased its portfolio allocation in CRSP by 32.30% over the last quarter.
UBS Group holds 2,844K shares representing 3.13% ownership of the company. In its prior filing, the firm reported owning 2,072K shares , representing an increase of 27.14%. The firm increased its portfolio allocation in CRSP by 84.74% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
